Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer

Drugs and Aging

Volumn 20, Issue 3, 2003, Pages 175-183

  Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GONADORELIN AGONIST; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AGED; ALCOHOL CONSUMPTION; BONE DENSITY; BONE MINERAL; DIET SUPPLEMENTATION; DRUG EFFICACY; EXERCISE; FRACTURE; HIP; HUMAN; LIFESTYLE; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SMOKING CESSATION; SPINE; WEIGHT BEARING;

ANDROGEN ANTAGONISTS; BONE DENSITY; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 0037288323     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320030-00002     Document Type: Review

References (61)

1. Siddiqui NA, Shetty KR, Duthie Jr EH. Osteoporosis in older men: discovering when and how to treat it. Geriatrics 1999; 54: 20-2, 27-8, 30 passim
2. Seeman E. The structural basis of bone fragility in men. Bone 1999; 25: 143-7
3. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998; 27: 349-67
4. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999; 84: 3431-4
5. Agency for Health Care Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Summary, evidence report/technology assessment: No. 4. Available from URL: http://ahrq.gov/clinic/prossumm.htm [Accessed 1999 Apr 30]
6. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001; 166: 508-15
7. Coleman RE. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol 2001; 28: 35-41
8. Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women: The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263: 665-8
9. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-5
10. Gardsell P, Johnell O, Nilsson B E. The predictive value of forearm bone mineral content measurements in men. Bone 1990; 11: 229-32
11. Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991; 115: 837-42
12. Kanis JA, Melton III LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-41
13. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-46
14. Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporos Int 2000; 11: 153-7
15. Szulc P, Marchand F, Duboeuf F, et al. Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone 2000; 26: 123-9
16. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-7
17. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389-406
18. Zmuda JM, Cauley JA, Glynn NW, et al. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 2000; 15: 1417-24
19. Finkelstein JS, Cleary RL, Butler JP, et al. A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab 1994; 78: 724-30
20. Grampp S, Jergas M, Gluer CC, et al. Radiologic diagnosis of osteoporosis: current methods and perspectives. Radiol Clin North Am 1993; 31: 1133-45
21. Schutte HE, Park WM. The diagnostic value of bone scintigraphy in patients with low back pain. Skeletal Radiol 1983; 10: 1-4
22. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001; 345: 948-55
23. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-22
24. Leder BZ, Smith MR, Fallon MA, et al. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001; 86: 511-6
25. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100: 1755-9
26. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-74
27. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997; 12: 1833-43
28. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85: 219-23
29. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-61
30. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-98
31. Bilezikian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339: 599-603
32. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555-61
33. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995; 57: 97-9
34. Scherr D, Pitts Jr WR, Vaughn Jr ED. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167: 535-8
35. Sieber PR, Keliier DL, Kahnoski RJ, et al. Bone mineral density is maintained during bicalutamide ('Casodex') treatment. Proc Am Soc Clin Oncol 2002; 21: 196a
36. Robson M, Dawson N. How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996; 10: 727-47
37. Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt) 1998; 12: 499-505
38. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-6
39. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44
40. Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-50
41. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 449-52
42. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8
43. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6
44. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-7
45. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001; 91: 2238-45
46. Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-6
47. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92: 1444-50
48. Goldray D, Weisman Y, Jaccard N, et al. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993; 76: 288-90
49. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603
50. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-56
51. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
52. Giovannucci E, Rimm EB, Wolk A, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442-7
53. Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9: 559-66
54. Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998; 9: 567-82
55. Thiebaud D, Burckhardt P, Melchior J, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994; 4: 76-83
56. Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997; 61: 266-71
57. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9 (5): 745-51
58. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61
59. Smith MR, Eastham J, Gleason D, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol; In press
60. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10
61. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86: 5252-5